← Back to patent-cliff list
Secutrelvir
Tier C — Watch / tradeSecutrelvir
Shionogi & Co., Ltd.
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：3CLp
Indications (approved)：COVID-19, Renal impairment
Regional status
US
Phase III
2026-09-14
EU
Phase III
2026-09-14
China
-
Japan
Phase III
2026-08-05
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Secutrelvir?
Approved indications include: COVID-19, Renal impairment.
When does the Secutrelvir patent expire?
No public expiry year is available for Secutrelvir yet; this page updates once verified.
How do I get a quote for Secutrelvir intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29